Management of Bronchial Carcinoids: International Practice Survey Among the European Society of Thoracic Surgeons

References

• Travis WD . Lung tumors with neuroendocrine differentiation. Eur. J. Cancer45(Suppl. 1), 251–266 (2009).
   PubMedGoogle Scholar
• Righi L , VolanteM, RapaI, ScagliottiGV, PapottiM. Neuro-endocrine tumors of the lung. A review of relevant pathological and molecular data. Virchows Arch.45(Suppl. 1), S51–S59 (2007).
   Google Scholar
• Fink G , KrelbaumT, YellinAet al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest119(6), 1647–1651 (2001).
   PubMed Web of Science ®Google Scholar
• Gustafsson BI , KiddM, ChanA, MalfertheinerMV, ModlinIM. Bronchopulmonary neuroendocrine tumors. Cancer113(1), 5–21 (2008).
   PubMed Web of Science ®Google Scholar
• Travis WD . Advances in neuroendocrine lung tumors. Ann. Oncol.21(Suppl. 7), 65–71 (2010).
   Google Scholar
• Kruger S , BuckAK, BlumsteinNMet al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumors. J. Intern. Med.260(6), 545–550 (2006).
   PubMed Web of Science ®Google Scholar
• Chong S , LeeKS, KimBTet al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am. J. Roentgenol.188(5), 1223–1231 (2007).
   PubMed Web of Science ®Google Scholar
• Erasmus JJ , MacapinlacHA. Low-sensitivity FDG-PET studies: less common lung neoplasms. Semin. Nucl. Med.42(4), 255–260 (2012).
   PubMed Web of Science ®Google Scholar
• Ambrosini V , CastellucciP, RubelloDet al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl. Med. Commun.30(4), 281–286 (2009).
   PubMed Web of Science ®Google Scholar
• Kayani I , ConryBG, GrovesAMet al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med.50(12), 927–1932 (2009).
   PubMed Web of Science ®Google Scholar
• Jindal T , KumarA, KumarR, DuttaR. Role of 68Ga-DOTATOC PET/CT in carcinoids. Pathol. Int.60(2), 143–144 (2010).
   PubMed Web of Science ®Google Scholar
• Lardinois D , De LeynP, Van SchilPet al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur. J. Cardiothorac. Surg.30(5), 787–792 (2006).
   PubMed Web of Science ®Google Scholar
• Akerstrom G , FalconiM, KianmaneshRet al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology90(2), 203–208 (2009).
   PubMed Web of Science ®Google Scholar
• Kos-Kudla B , O’TooleD, FalconiMet al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology91(4), 341–350 (2010).
   PubMed Web of Science ®Google Scholar
• O’Toole D , RindiG, PlockingerU, WiedenmannB, Enets. ENETS consensus guidelines for the management of patients with rare metastases from digestive neuroendocrine tumors: rationale and working framework. Introduction. Neuroendocrinology91(4), 324–325 (2010).
   PubMed Web of Science ®Google Scholar
• Detterbeck FC . Management of carcinoid tumors. Ann. Thorac. Surg.89(3), 998–1005 (2010).
   PubMed Web of Science ®Google Scholar
• Caplin ME , BaudinE, FerollaP. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol.26(8), 1604–1620 (2015).
   PubMed Web of Science ®Google Scholar
• Garcia-Yuste M , MatillaJM, Alvarez-GagoTet al. Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Ann. Thorac. Surg.70(1), 258–263 (2010).
   Google Scholar
• Filosso PL , RenaO, DonatiGet al. Bronchial carcinoid tumors: surgical management and long-term outcome. J. Thorac. Cardiovasc. Surg.123(2), 303–309 (2002).
   PubMed Web of Science ®Google Scholar
• Cardillo G , SeraF, Di MartinoMet al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann. Thorac. Surg.77(5), 1781–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Daddi N , FerollaP, UrbaniMet al. Surgical treatment of neuroendocrine tumors of the lung. Eur. J. Cardiothorac. Surg.26(4), 813–817 (2004).
   PubMed Web of Science ®Google Scholar
• Rea F , RizzardiG, ZuinAet al. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur. J. Cardiothorac. Surg.31(2), 186–191 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Yuste M , MatillaJM, CuetoAet al. Typical and atypical carcinoid tumors: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumors of the Lung. Eur. J. Cardiothorac. Surg.31(2), 192–197 (2007).
   PubMed Web of Science ®Google Scholar
• Filosso PL , GuerreraF, EvangelistaAet al. SPrognostic model of survival for typical bronchial carcinoid tumors: Analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumors Working Group. Eur. J. Cardiothorac. Surg.48(3), 441–447 (2015).
   PubMed Web of Science ®Google Scholar
• Skuladottir H , HirschFR, HansenHH, OlsenJH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer37(2), 127–135 (2002).
   PubMed Web of Science ®Google Scholar
• Filosso PL , OliaroA, RuffiniEet al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J. Thorac. Oncol.8(10), 1282–1288 (2013).
   PubMed Web of Science ®Google Scholar
• Jeung MY , GasserB, GangiAet al. Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings. Radiographics22(2), 351–365 (2002).
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ , KrenningEP, ScheidhauerKet al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with 111In-pentetreotide. Neuroendocrinology90(2), 184–189 (2009).
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ , KrenningEP, BakkerWH, OeiHY, KooijPP, LambertsSW. Somatostatin analogue scintigraphy in carcinoid tumors. Eur. J. Nucl. Med.20(4), 283–292 (1993).
   PubMedGoogle Scholar
• Lococo F , TregliaG. Which is the best strategy for diagnosing bronchial carcinoid tumors? The role of dual tracer PET/CT scan. Hell. J. Nucl. Med.7(1), 7–9 (2014).
   Google Scholar
• Baudin E , BidartJM, BachelotAet al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann. Oncol.12(Suppl. 2), S79–S82 (2001).
   PubMed Web of Science ®Google Scholar
• Modlin IM , GustafssonBI, MossSF, PavelM, TsolakisAV, KiddM. Chromogranin A – biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol.17(9), 2427–2443 (2010).
   PubMed Web of Science ®Google Scholar
• Zatelli MC , MinoiaM, MartiniCet al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr. Relat. Cancer17(3), 719–729 (2010).
   PubMed Web of Science ®Google Scholar
• O’Toole D , GrossmanA, GrossDet al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology90(2), 194–202 (2009).
   PubMed Web of Science ®Google Scholar
• Dong M , YaoJC. mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr. Relat. Cancer18(3), C15–C18 (2011).
   PubMed Web of Science ®Google Scholar
• Pavel ME , HainsworthJD, BaudinEet al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase 3 study. Lancet378(9808), 2005–2012 (2011).
   PubMed Web of Science ®Google Scholar
• Ekeblad S , SundinA, JansonETet al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res.13(10), 2986–2991 (2007).
   PubMed Web of Science ®Google Scholar
• Kulke MH , StuartK, EnzingerPCet al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J. Clin. Oncol.24(3), 401–406 (2006).
   PubMed Web of Science ®Google Scholar
• Yao JC , FazioN, SinghSet al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumors of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, Phase 3 study. Lancet387(10022), 968–977 (2015).
   PubMed Web of Science ®Google Scholar
• Beshay M , RothT, SteinR, SchmidRA. Synchronous bilateral typical pulmonary carcinoid tumors. Eur. J. Cardiothorac. Surg.23(2), 251–253 (2003).
   PubMed Web of Science ®Google Scholar
• Spaggiari L , VeronesiG, GasparriR, PelosiG. Synchronous bilateral lung carcinoid tumors: a rare entity?Eur. J. Cardiothorac. Surg.24(2), 334 (2003).
   PubMed Web of Science ®Google Scholar
• Rea F , RizzardiG, MarulliG, BortolottiL. Metachronous bronchial carcinoid tumor. Eur. J. Cardiothorac. Surg.30(2), 394–396 (2006).
   PubMed Web of Science ®Google Scholar
• Yuncu G , SevincS, OzturkB, KiterG, BirF, KarabulutN. Bilateral sleeve lobectomy for synchronized bilateral central carcinoid tumor. J. Thorac. Cardiovasc. Surg.133(6), 1660–1661 (2007).
   PubMed Web of Science ®Google Scholar
• Arnold R , ChenYJ, CostaFet al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology90(2), 227–233 (2009).
   PubMed Web of Science ®Google Scholar
• Filosso PL , FerollaP, GuerreraFet al. Multidisciplinary management of advanced lung neuroendocrine tumors. J. Thorac. Dis.7(Suppl. 2), S163–S171 (2015).
   PubMedGoogle Scholar